Lexeo Therapeutics agrees to buy Mantle Therapeutics for up to $21.3 million

• Lexeo Therapeutics reached a definitive agreement to acquire Mantle Therapeutics, adding several frataxin-restoration programs targeting Friedreich ataxia neurology.
• Consideration totals USD 8.3 million upfront in cash and equity, with up to USD 13 million in milestone payments in cash and equity.
• Deal value could reach USD 21.3 million; closing is expected in the third quarter of 2026, subject to customary conditions.
• Acquired assets include a clinical-stage oral combination therapy, a preclinical CNS-penetrant small molecule, and TfR1-based brain-delivery biologics.
• Cash runway guidance remains into 2028; an IND for the next FA development candidate is targeted for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220700PRIMZONEFULLFEED9831067) on September 22, 2026, and is solely responsible for the information contained therein.